| 227.25 -0.04 (-0.02%) | 01-30 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 268.63 | 1-year : | 313.77 |
| Resists | First : | 230 | Second : | 268.63 |
| Pivot price | 219.17  |
|||
| Supports | First : | 212.02 | Second : | 200.91 |
| MAs | MA(5) : | 225.63 |
MA(20) : | 215.86 |
| MA(100) : | 198.15 |
MA(250) : | 175.67 |
|
| MACD | MACD : | 5.3 |
Signal : | 4.3 |
| %K %D | K(14,3) : | 91.8 |
D(3) : | 93.9 |
| RSI | RSI(14): 77.1 |
|||
| 52-week | High : | 230 | Low : | 141.5 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ JNJ ] has closed below upper band by 17.5%. Bollinger Bands are 81.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 10 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 228.74 - 229.98 | 229.98 - 231.02 |
| Low: | 222.26 - 223.84 | 223.84 - 225.15 |
| Close: | 224.86 - 227.28 | 227.28 - 229.29 |
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Fri, 30 Jan 2026
Graham threatens shutdown deal over House-backed repeal, warns Johnson: 'I won't forget this' - Fox News
Fri, 30 Jan 2026
Yvonne Johnson Obituary (2026) - Baldwinsville, NY - Syracuse.com
Fri, 30 Jan 2026
Spurs' Keldon Johnson celebrates Gregg Popovich's birthday with heartfelt words - San Antonio Express-News
Fri, 30 Jan 2026
Johnson: Nicki Minaj’s music not ‘necessarily my genre’ but she’s become a ‘friend of mine’ - The Hill
Fri, 30 Jan 2026
Reform UK enlists Boris Johnson ally to write party nature policies - The Guardian
Fri, 30 Jan 2026
Johnson says government will 'inevitably' shut down despite Senate deal - USA Today
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 2,410 (M) |
| Shares Float | 2,410 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 75 (%) |
| Shares Short | 20,430 (K) |
| Shares Short P.Month | 23,910 (K) |
| EPS | 10.34 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 32.95 |
| Profit Margin | 27.2 % |
| Operating Margin | 30.2 % |
| Return on Assets (ttm) | 8.2 % |
| Return on Equity (ttm) | 33.6 % |
| Qtrly Rev. Growth | 6.8 % |
| Gross Profit (p.s.) | 26.13 |
| Sales Per Share | 38.23 |
| EBITDA (p.s.) | 13.24 |
| Qtrly Earnings Growth | 91 % |
| Operating Cash Flow | 24,200 (M) |
| Levered Free Cash Flow | 12,010 (M) |
| PE Ratio | 21.97 |
| PEG Ratio | 0 |
| Price to Book value | 6.89 |
| Price to Sales | 5.94 |
| Price to Cash Flow | 22.63 |
| Dividend | 1.29 |
| Forward Dividend | 0 |
| Dividend Yield | 0.5% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |